A Phase 2, dose- range finding, 12-week, double-blind, randomized, parallel group study to evaluate safety and efficacy of GRC 27864 in patients with moderate osteoarthritis pain
Phase of Trial: Phase II
Latest Information Update: 17 Sep 2018
At a glance
- Drugs GRC 27864 (Primary)
- Indications Pain
- Focus Therapeutic Use
- Sponsors Glenmark Pharmaceuticals Ltd
- 26 Jun 2018 Planned End Date changed to 25 Mar 2019.
- 18 Jan 2018 New trial record
- 15 Jan 2018 According to a Glenmark Pharmaceuticals media release, the Directorate General of Health Services, Central Drugs Standard Control Organization (CDSCO), Government of India has granted permission to conduct this trial.